Nanologica AB engages in the research and development of pharmaceutical products. It operates through Chromatography and Drug Development segments. The Chromatography segment include separation method based on the fact that different substance pass through a chromatography column at different paces. The Drug Development segment comprises development of new drugs or improving existing drugs on the market. The company was founded by Alfonso Garcia-Bennett in 2004 and is headquartered in Sodertalje, Sweden.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company